Effects of ACEI on Bone Turnover

The University of Texas Health Science Center, Houston32 enrolled

Overview

The investigators hypothesize that older persons (≥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bone Turnover Status in Hypertensive Patients

Eligibility

Sex: ALLMin age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * at least 45 years of age * a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control * able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment). Exclusion Criteria: * younger than 45 years of age * a diagnosis of metabolic bone disease * a diagnosis of osteoporosis or use of medication to treat osteoporosis * a diagnosis of diabetes mellitus, or renal insufficiency, or cancer * history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.

Locations (2)

Nahid Rianon, MD

Houston, Texas, United States

University of Texas Medical School at Houston

Houston, Texas, United States

Outcomes

Primary Outcomes

Change in serum CTX levels in pg/mL

Time frame: baseline, 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.